Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Incyte Corporation INCY

Healthcare  —  Biotechnology
123.36 (1.46) (1.17%) as of 29 Sep
Market cap
$26.1B
P/E
15.4×
S&P 500 Member Revenue Champion (10y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Incyte Corporation (INCY) EV/EBITDA

As of 28 September 2026, Incyte Corporation (INCY) trades at a EV/EBITDA of 10.9×. Over the past ten years it has ranged from 0.0× (March 2021) to 99,927× (August 2017); the current reading is higher than 28% of that period. That is above the Biotechnology industry median of 0.7× and in line with the Healthcare sector median of 10.5×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 9.8× (87.91%)
FY2024 80.9× 416.50%
FY2023 15.7× (29.87%)
FY2022 22.3× 3.64%
FY2021 21.6× —
FY2020 0.0× —
FY2019 36.6× (44.28%)
FY2018 65.6× —
FY2017 0.0× —
FY2016 93.7× (53.82%)

Quarterly

Period EV/EBITDA Change
Jun 2026 9.7× 11.98%
Mar 2026 8.7× (11.43%)
Dec 2025 9.8× 12.30%
Sep 2025 8.7× 2.49%
42 more quarters

Against its own ten years

Low 0.0× High 99,927×
Ten-year median 22.2×
Current reading's percentile 28

EV/EBITDA against peers

Company EV/EBITDA
BNTX BioNTech SE Sponsored ADR compare n/m
ROIV Roivant Sciences Ltd. compare n/m
INSM Insmed, Inc. compare n/m
JAZZ Jazz Pharmaceuticals PLC compare 10.7×
INCY Incyte Corporation 10.9×
GMAB Genmab A/S Sponsored ADR compare 21.7×
RPRX Royalty Pharma PLC compare 22.0×
ALNY Alnylam Pharmaceuticals, Inc. compare 30.2×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 34.7×
Biotechnology industry median 0.7×
Healthcare sector median 10.5×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on INCY